CLEVELAND – September 30, 2015
OptiKira has been awarded two NIH grants to support the development of novel therapeutics that prevent cell death caused by misfolded or unfolded proteins. The company’s technology has application for diseases such as retinitis pigmentosa, diabetes, and ALS.

Optikira, launched by BioMotiv, is based on technology from Harrington Scholars at UCSF and collaborators from the University of Washington.

Click here to read more